

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION OF

Mitchell E. Reff et al.

Application No. 09/292,053

Filed: April 14, 2001

Title: Gamma-1 Anti-Human CD23 Monoclonal Antibodies and Use Thereof as Therapeutics



Group Art Unit: 1644

Examiner: M. Dibrino

12#9

* * * * *

STATUS INQUIRY

Hon. Commissioner of Patents
Washington, D.C. 20231

RECEIVED
APR 29 2002
TECH CENTER 1600/2900

Sir:

This communication is being filed to determine the status of this application.

To date, Applicants have not received any communication responding to the §116 Response and the Notice of Appeal to maintain pendency submitted on December 4, 2001.

It would be appreciated if the Examiner could provide Applicant with the status as soon as possible, especially as this application is after Notice of Appeal.

If the Examiner has any questions relating to this application, it is respectfully requested that the undersigned be contacted.

Respectfully submitted,
Pillsbury Winthrop LLP

By: Robin L. Teskin
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2200
(703) 905-2500 Facsimile

Date: April 25, 2002
Attorney Reference: 037003-0275739

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Reff et al.

Appl. No.: 09

292.053

Series Code ↑

Serial No. ↑

Filed: April 14, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231


Group Art Unit 1644

Examiner: M. Dibrino

Atty. Dkt. P 0275739 1997-30-0565D1

M#

Client Ref

Appl. Title: Gamma-1 Anti-Human CD23
Monoclonal Antibodies and Use Thereof
as Therapeutics

RECEIVED

Sir:

REPLY/AMENDMENT/LETTER

Date: April 25, 2002

APR 29 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of ~~some data and subject~~ ^{TECHNICAL DATA} 2900 which is incorporated hereto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A <input checked="" type="checkbox"/> NOT made B <input type="checkbox"/> Withdrawn C <input type="checkbox"/> made herewith D <input type="checkbox"/> made previously		For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims				**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims				***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date:				<input checked="" type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo)	\$110/\$55 =				115/215
				(2 mos)	\$400/\$200 =		+ \$0		116/216
				(3 mos)	\$920/\$460 =				117/217
				(Usable only for ≤ 2mo.OA --- 4 mos)	\$1,440/\$720=				118/218
				(Usable only for 30 day/1mo.OA --- 5 mos)	\$1,960/\$980=				128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0					
8.				Extension Fee Attached + \$0					
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55 + \$0 148/248					
10. If IDS attached requires Official Fee under Rule 97 (c),				+ \$180 + \$0 126					
or if Rule 97(d) Request				+ \$180 + \$0 126					
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$740/370 + \$0 146/246					
12. No. of additional inventions for examination per Rule 129(b).....				x \$740/370 ea + \$0 149/249					
13. Request for Continued Examination (RCE)				+ \$740/370 + \$0 1179/1279					
14. Status Inquiry				+ \$0					
15.				TOTAL FEE ENCLOSED = \$0					

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275739

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP

Intellectual Property Group

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

By Atty: Robin L. Teskin

Sig:

Reg. No. 35,030

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/lak

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments